



**Method Change for
Carcinoembryonic Antigen (CEA)
and Cancer Antigen 125 (CA-125) Assays**

Laboratory Alliance of Central New York currently uses the Beckman Coulter Access DXI chemiluminescence immunoassay method for analysis of carcinoembryonic antigen (CEA) and the Siemens Immulite 2000XPi for analysis of cancer antigen 125 (CA-125). Due to consolidation of immunoassay instrumentation, we are transitioning both assays to a new platform, the Siemens Centaur XPT.

Because of the change in methodologies, as of July 16, 2018 we will report results from the old and new methods for each assay for a period of three months so that providers can correlate results between methods and re-baseline patients. Effective October 16, 2018, results will be reported only from the new Centaur method.

No changes to order codes or specimen collection will be required at this time. The duplicate testing to be performed will be reflexively added by Laboratory Alliance and performed at no charge to the patient. Results from the new method will be reported on the same day as the old method. Interpretive comments appended to results from both methods include reference range and assays used.

For questions about CEA or CA 125 analysis at Laboratory Alliance, please contact Dr. Roy Huchzermeier at 315-410-7221 or RoyHuchzermeierPhD@lacny.com or Cheryl Haskins at 315-410-7014 or CherylHaskins@lacny.com.

cmh, 6/25/18